Psychiatric Genomics, Visualized.

An interactive reference distilling four lecture series — pharmacogenomics, root-cause genomics, nutrigenomics, and treatment-resistant depression — into a single tool you can use at the point of care.

The Curriculum

Three educators, four lecture series, ~10 hours of clinical material. Each module builds on the last.

1
Pharmacogenomics

Reed & Dickerson on CYP450 metabolism, ion-channel gates (ANK3, CACNA1C), pharmacodynamic genes (HTR2A, SLC6A4, COMT, BDNF, ADRA2A, DRD2, OPRM1), and HLA-mediated SJS risk.

CYP2D6 CYP2C19 ANK3 CACNA1C
→ 4 lectures
2
Root Cause Genomics

Hausman-Cohen on the IntellxxDNA framework — moving beyond drug metabolism to the underlying biological drivers (HTR1A, NPSR1, DIO2, ESR2, BDNF, MTHFD1L, F2, GCH1, and dozens more).

HTR1A NPSR1 DIO2 ESR2
→ 4 lectures
3
Treatment-Resistant Depression

Kraker on the CNR1 tri-loop pathway, kynurenine shunt of inflammation, NF-κB master switch, and the ‘Catherine’ case — 41 yo with 25 years of partial responders, 53 lbs lost, recovered.

CNR1 IL-6 DBH NBPF3
→ 1 lecture

The Big Picture

99.5%
of UK Biobank participants may have an atypical response to at least one drug (McInnes 2021)
24%
have already been prescribed a drug for which they are predicted to have an atypical response (McInnes 2021)
$136 B
annual cost of adverse drug events in the U.S.
3rd
leading cause of death in the U.S. — adverse drug events (March 2025)
20%
remission rate of TRD with even outstanding pharmacogenomics alone
256
DSM symptom combinations that all qualify as ‘major depressive disorder’
66%
PHQ-9 reduction with low-dose lithium in CACNA1C carriers (Dickerson & Reed 2023)
3.2%
prevalence of two aberrant CNR1 copies — devastating, treatable

How To Use This Reference

At the bedside

When a PGx report comes back, search the gene symbol in the bar above (or press /). Each gene page lists alleles, phenotype frequencies, and evidence-based interventions — both pharmacologic and nutraceutical.

Open Gene Atlas →

For learning

Walk through the visualized pathways — methylation, neurotransmitter synthesis, the CNR1 tri-loop, the inflammation→brain pipeline. Each diagram links to the genes that matter at every step.

View Pathways →

For your patient

The Quick Reference page gives printable gene-cards and ‘refrigerator versions’ of supplement protocols organized by phenotype.

Print References →

For deeper study

All ten lecture transcripts and slide decks are searchable in the Lecture Library — every quote, every dose, every case.

Open Library →

Key Frameworks

Pharmacogenomics vs. Root Cause

Pharmacogenomics tells you which drug to use. Root-cause genomics asks why this person is depressed — is it serotonin synthesis (TPH/BH4)? Methylation (MTHFR/MTRR)? Inflammation (IL-6/TNF-α)? Estrogen (ESR2)? Endocannabinoid (CNR1)?

Pharmacogenomics alone gets ~20% of treatment-resistant patients to remission. Root cause genomics targets the other 80%.

Treat the gates first

Sodium fires (ANK3) → calcium opens (CACNA1C) → all neurotransmitters release. Disrupted gates = mood instability. Lithium is the only common drug that works on both gates. Stabilize gates → then add antidepressant or methylfolate.

‘Lithium is the cake. Everything else is the icing.’ — Reed

Form matters

Methylfolate ≠ folic acid (and not everyone needs methylfolate — some need folinic). P5P ≠ pyridoxine (the latter is neurotoxic in carriers). Methyl- + adenosyl-cobalamin ≠ cyanocobalamin. Magnesium L-threonate ≠ other magnesiums for brain effects.

‘Put out the fire first’

Before remodeling — address the fundamentals: inflammation, oxidative stress, gut, nutrients. Magnesium, B12, folate, zinc, vitamin C and D, and gluten removal (when HLA-DQ2.5 +) often produce dramatic gains before any neurotransmitter intervention.

Trusted External Sources

FDA Table
Pharmacogenetic associations with sufficient clinical evidence — actively curated by the FDA.
CPIC Guidelines
Clinical Pharmacogenetics Implementation Consortium — standardized terminology and dosing.
DPWG
Dutch Pharmacogenetics Working Group — therapeutic dose recommendations integrated with EHRs.